Sedat Yildirim
Overview
Explore the profile of Sedat Yildirim including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
109
Citations
589
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sever O, Basoglu T, Yildirim S
J Clin Med
. 2025 Feb;
14(4).
PMID: 40004832
: Colorectal cancer (CRC) remains a global health challenge. Metabolic disorders, including dyslipidemia, have been linked to CRC progression, yet the relationship between lipid profiles, tumor location, and survival outcomes...
2.
Gojayev A, Erkent M, Aydin H, Aydogan C, Avci T, Tirnova I, et al.
Med Sci Monit
. 2025 Feb;
31:e947466.
PMID: 39995244
BACKGROUND Pilonidal sinus is a chronic or acute infectious disease in the intergluteal cleft. Various surgical treatments exist, but optimal management remains debated. This study compares outcomes of primary midline...
3.
Colak R, Gulturk I, Dinc G, Akdag G, Yildirim S, Yilmaz M, et al.
J Chemother
. 2025 Feb;
:1-7.
PMID: 39988757
Introduction: Immunotherapies have increased the therapeutic options for patients with metastatic renal cell carcinoma (mRCC), but the absence of prognostic indicators remains unresolved. We assessed the potential association of BMI...
4.
Onan E, Canpolat T, Yildirim S, Caliskan K, Haberal M
Clin Transplant
. 2025 Feb;
39(2):e70102.
PMID: 39918425
No abstract available.
5.
Dogan A, Ilhan N, Akdag G, Yildirim S, Seyyar M, Yuksel Yasar Z, et al.
Medicina (Kaunas)
. 2025 Jan;
61(1.
PMID: 39859134
: Early-onset breast cancer (EOBC), particularly in patients under 40, presents with distinct biological characteristics and worse survival outcomes compared to late-onset cases. Despite intensive treatments, EOBC patients, especially those...
6.
Sever N, Yildirim S, Gurbuz A, Karakas Kilic D, Zeynelgil E, Altintas Y, et al.
Medicina (Kaunas)
. 2025 Jan;
61(1).
PMID: 39859125
Malignant pleural mesothelioma (MPM) is a rare and aggressive malignancy with a poor prognosis. Identifying reliable prognostic factors is crucial for risk stratification and optimizing treatment strategies. This study aimed...
7.
Sekmek S, Ozsan Celebi S, Bayram D, Erol C, Kos F, Sendur M, et al.
Sci Rep
. 2024 Nov;
14(1):29785.
PMID: 39616250
We aimed to compare FOLFIRI and bevacizumab with FOLFIRI and aflibercept in terms of overall survival (OS), progression-free survival (PFS) and safety in patients with RAS-mutant metastatic colon cancer who...
8.
Safak A, Karakaya E, Varan B, Ozcay F, Cekmen N, Yildirim S, et al.
Exp Clin Transplant
. 2024 Nov;
22(Suppl 5):94-99.
PMID: 39498928
Objectives: Alagille syndrome is an autosomal recessive disorder with multisystemic involvement. Patients with Alagille syndrome have many accompanying anomalies such as atypical facial appearance, posterior embryotoxon, butterfly vertebra, cardiac anomalies,...
9.
Evaluating the Effectiveness of Nivolumab in Metastatic Lung Cancer Among Patients Aged 65 and Older
Isik D, Alan O, Akdag G, Yildirim S, Kinikoglu O, Altintas Y, et al.
J Clin Med
. 2024 Oct;
13(20).
PMID: 39458213
Lung cancer remains the leading cause of cancer-related mortality globally, predominantly affecting older individuals. Despite the increasing use of immune checkpoint inhibitors (ICIs) like nivolumab in non-small cell lung cancer...
10.
Yildirim S, Alan O, Yuksel Yasar Z, Kaya T, Akdag G, Kinikoglu O, et al.
Medicina (Kaunas)
. 2024 Aug;
60(8).
PMID: 39202654
: Lung cancer is the leading cause of cancer-related deaths. Spread through air spaces (STAS) is an adverse prognostic factor that has become increasingly known in recent years. This study...